Viatris Inc. (VTRS)
USD 7.33
(-3.81%)
USD 7.33
(-3.81%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 16.18 Billion USD | -10.14% |
| 2022 | 18.01 Billion USD | -8.63% |
| 2021 | 19.71 Billion USD | -12.09% |
| 2020 | 22.42 Billion USD | 100.01% |
| 2019 | 11.21 Billion USD | -14.79% |
| 2018 | 13.16 Billion USD | 2.3% |
| 2017 | 12.86 Billion USD | -15.38% |
| 2016 | 15.2 Billion USD | 141.48% |
| 2015 | 6.29 Billion USD | 10.45% |
| 2014 | 5.69 Billion USD | -24.87% |
| 2013 | 7.58 Billion USD | 42.14% |
| 2012 | 5.33 Billion USD | 19.16% |
| 2011 | 4.47 Billion USD | -14.9% |
| 2010 | 5.26 Billion USD | 5.58% |
| 2009 | 4.98 Billion USD | -1.85% |
| 2008 | 5.07 Billion USD | 7.91% |
| 2007 | 4.7 Billion USD | 0.0% |
| 2006 | 685.18 Million USD | 3445.6% |
| 2005 | 685.18 Million USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | 21.85 Million USD | -6.39% |
| 2001 | 23.34 Million USD | -23.78% |
| 2000 | 30.63 Million USD | 14.29% |
| 1999 | 26.8 Million USD | 2.29% |
| 1998 | 26.2 Million USD | -19.63% |
| 1997 | 32.6 Million USD | 81.11% |
| 1996 | 18 Million USD | 153.52% |
| 1995 | 7.1 Million USD | 54.35% |
| 1994 | 4.6 Million USD | -9.8% |
| 1993 | 5.1 Million USD | 41.67% |
| 1992 | 3.6 Million USD | 71.43% |
| 1991 | 2.1 Million USD | 90.91% |
| 1990 | 1.1 Million USD | 120.0% |
| 1989 | 500 Thousand USD | -92.06% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 14.73 Billion USD | -8.35% |
| 2024 Q1 | 16.07 Billion USD | -0.71% |
| 2023 FY | 16.18 Billion USD | -10.14% |
| 2023 Q4 | 16.18 Billion USD | -5.2% |
| 2023 Q3 | 17.07 Billion USD | -0.98% |
| 2023 Q1 | 18.06 Billion USD | 0.3% |
| 2023 Q2 | 17.24 Billion USD | -4.56% |
| 2022 Q4 | 18.01 Billion USD | -3.79% |
| 2022 FY | 18.01 Billion USD | -8.63% |
| 2022 Q1 | 18.76 Billion USD | -4.84% |
| 2022 Q2 | 19.2 Billion USD | 2.37% |
| 2022 Q3 | 18.72 Billion USD | -2.51% |
| 2021 Q2 | 20.91 Billion USD | -5.36% |
| 2021 Q3 | 19.85 Billion USD | -5.08% |
| 2021 Q4 | 19.71 Billion USD | -0.69% |
| 2021 FY | 19.71 Billion USD | -12.98% |
| 2021 Q1 | 22.1 Billion USD | -1.46% |
| 2020 Q1 | 11.19 Billion USD | -0.15% |
| 2020 Q2 | 8.99 Billion USD | -19.68% |
| 2020 Q3 | 9.1 Billion USD | 1.19% |
| 2020 Q4 | 22.42 Billion USD | 146.43% |
| 2020 FY | 22.65 Billion USD | 102.05% |
| 2019 Q3 | 12.46 Billion USD | -1.03% |
| 2019 Q4 | 11.21 Billion USD | -10.0% |
| 2019 Q1 | 13.08 Billion USD | -0.56% |
| 2019 FY | 11.21 Billion USD | -14.79% |
| 2019 Q2 | 12.59 Billion USD | -3.8% |
| 2018 Q2 | 13.32 Billion USD | 6.98% |
| 2018 FY | 13.16 Billion USD | 2.3% |
| 2018 Q4 | 13.16 Billion USD | -0.98% |
| 2018 Q3 | 13.29 Billion USD | -0.21% |
| 2018 Q1 | 12.45 Billion USD | -3.22% |
| 2017 Q3 | 13.99 Billion USD | -0.24% |
| 2017 FY | 12.86 Billion USD | -15.38% |
| 2017 Q4 | 12.86 Billion USD | -8.06% |
| 2017 Q2 | 14.02 Billion USD | -4.59% |
| 2017 Q1 | 14.7 Billion USD | -3.3% |
| 2016 Q4 | 15.2 Billion USD | 34.2% |
| 2016 Q2 | 12.77 Billion USD | 101.92% |
| 2016 Q3 | 11.32 Billion USD | -11.31% |
| 2016 FY | 15.2 Billion USD | 141.48% |
| 2016 Q1 | 6.32 Billion USD | 0.48% |
| 2015 Q3 | 5.84 Billion USD | -0.76% |
| 2015 Q1 | 5.75 Billion USD | 0.89% |
| 2015 Q2 | 5.89 Billion USD | 2.43% |
| 2015 Q4 | 6.29 Billion USD | 7.69% |
| 2015 FY | 6.29 Billion USD | 9.82% |
| 2014 Q2 | 7.91 Billion USD | 1.77% |
| 2014 Q4 | 5.69 Billion USD | -0.41% |
| 2014 Q1 | 7.78 Billion USD | 2.56% |
| 2014 Q3 | 5.72 Billion USD | -27.72% |
| 2014 FY | 5.73 Billion USD | -24.43% |
| 2013 FY | 7.58 Billion USD | 42.14% |
| 2013 Q1 | 5.67 Billion USD | 6.28% |
| 2013 Q2 | 5.81 Billion USD | 2.47% |
| 2013 Q4 | 7.58 Billion USD | 31.27% |
| 2013 Q3 | 5.77 Billion USD | 0.0% |
| 2012 FY | 5.33 Billion USD | 19.16% |
| 2012 Q2 | 5.55 Billion USD | 13.15% |
| 2012 Q1 | 4.9 Billion USD | 9.54% |
| 2012 Q3 | 4.84 Billion USD | -12.7% |
| 2012 Q4 | 5.33 Billion USD | 10.12% |
| 2011 Q3 | 4.48 Billion USD | -7.16% |
| 2011 Q1 | 4.76 Billion USD | -9.43% |
| 2011 FY | 4.47 Billion USD | -14.9% |
| 2011 Q4 | 4.47 Billion USD | -0.09% |
| 2011 Q2 | 4.82 Billion USD | 1.31% |
| 2010 Q4 | 5.26 Billion USD | 0.98% |
| 2010 FY | 5.26 Billion USD | 5.58% |
| 2010 Q3 | 5.21 Billion USD | 3.27% |
| 2010 Q2 | 5.04 Billion USD | -0.21% |
| 2010 Q1 | 5.05 Billion USD | 1.47% |
| 2009 Q2 | 4.97 Billion USD | 0.28% |
| 2009 Q1 | 4.96 Billion USD | -3.89% |
| 2009 FY | 4.98 Billion USD | -3.49% |
| 2009 Q4 | 4.98 Billion USD | -2.8% |
| 2009 Q3 | 5.12 Billion USD | 3.02% |
| 2008 Q4 | 5.16 Billion USD | -0.87% |
| 2008 Q2 | 4.95 Billion USD | -0.43% |
| 2008 Q1 | 4.97 Billion USD | 0.0% |
| 2008 FY | 5.16 Billion USD | 5.13% |
| 2008 Q3 | 5.21 Billion USD | 5.21% |
| 2007 Q2 | 1.65 Billion USD | 0.07% |
| 2007 FY | 4.91 Billion USD | 617.09% |
| 2007 Q1 | 1.65 Billion USD | 140.89% |
| 2007 Q3 | 1.56 Billion USD | -5.23% |
| 2006 Q1 | 685.18 Million USD | -11.12% |
| 2006 Q2 | 687 Million USD | 0.26% |
| 2006 Q3 | 687 Million USD | 0.0% |
| 2006 Q4 | 687 Million USD | 0.0% |
| 2006 FY | 685.18 Million USD | 3445.6% |
| 2005 Q1 | 19.32 Million USD | 3.08% |
| 2005 FY | 19.32 Million USD | 1.02% |
| 2005 Q2 | 19.25 Million USD | -0.37% |
| 2005 Q3 | 791.95 Million USD | 4013.17% |
| 2005 Q4 | 770.87 Million USD | -2.66% |
| 2004 Q1 | 19.13 Million USD | -2.92% |
| 2004 Q4 | 18.74 Million USD | -0.07% |
| 2004 Q3 | 18.76 Million USD | -1.35% |
| 2004 FY | 19.13 Million USD | -4.08% |
| 2004 Q2 | 19.01 Million USD | -0.59% |
| 2003 Q4 | 19.7 Million USD | -1.86% |
| 2003 Q2 | 20.09 Million USD | 0.78% |
| 2003 Q1 | 19.94 Million USD | -4.39% |
| 2003 FY | 19.94 Million USD | -8.74% |
| 2003 Q3 | 20.08 Million USD | -0.09% |
| 2002 Q4 | 20.85 Million USD | -1.46% |
| 2002 Q3 | 21.16 Million USD | 7.25% |
| 2002 Q2 | 19.73 Million USD | -9.7% |
| 2002 FY | 21.85 Million USD | -6.39% |
| 2002 Q1 | 21.85 Million USD | -13.41% |
| 2001 Q2 | 22.15 Million USD | -5.11% |
| 2001 FY | 23.34 Million USD | -23.78% |
| 2001 Q4 | 25.23 Million USD | -5.43% |
| 2001 Q3 | 26.68 Million USD | 20.48% |
| 2001 Q1 | 23.34 Million USD | -7.87% |
| 2000 Q1 | 30.63 Million USD | 29.24% |
| 2000 Q3 | 26.7 Million USD | -18.65% |
| 2000 FY | 30.63 Million USD | 14.29% |
| 2000 Q4 | 25.34 Million USD | -5.12% |
| 2000 Q2 | 32.82 Million USD | 7.18% |
| 1999 Q1 | 26.8 Million USD | 5.1% |
| 1999 Q2 | 24.8 Million USD | -7.46% |
| 1999 Q3 | 24.1 Million USD | -2.82% |
| 1999 FY | 26.8 Million USD | 2.29% |
| 1999 Q4 | 23.7 Million USD | -1.66% |
| 1998 Q2 | 26.4 Million USD | 0.76% |
| 1998 Q1 | 26.2 Million USD | -18.13% |
| 1998 Q3 | 25.7 Million USD | -2.65% |
| 1998 Q4 | 25.5 Million USD | -0.78% |
| 1998 FY | 26.2 Million USD | -19.63% |
| 1997 Q3 | 32.2 Million USD | -2.13% |
| 1997 Q4 | 32 Million USD | -0.62% |
| 1997 Q1 | 32.6 Million USD | -33.47% |
| 1997 FY | 32.6 Million USD | 81.11% |
| 1997 Q2 | 32.9 Million USD | 0.92% |
| 1996 Q1 | 18 Million USD | 83.67% |
| 1996 Q4 | 49 Million USD | 1.66% |
| 1996 Q3 | 48.2 Million USD | 161.96% |
| 1996 Q2 | 18.4 Million USD | 2.22% |
| 1996 FY | 18 Million USD | 153.52% |
| 1995 FY | 7.1 Million USD | 54.35% |
| 1995 Q2 | 7.8 Million USD | 9.86% |
| 1995 Q1 | 7.1 Million USD | 51.06% |
| 1995 Q4 | 9.8 Million USD | 13.95% |
| 1995 Q3 | 8.6 Million USD | 10.26% |
| 1994 Q3 | 5.2 Million USD | 6.12% |
| 1994 Q1 | 4.6 Million USD | 4.55% |
| 1994 Q2 | 4.9 Million USD | 6.52% |
| 1994 Q4 | 4.7 Million USD | -9.62% |
| 1994 FY | 4.6 Million USD | -9.8% |
| 1993 Q1 | 5.1 Million USD | 6.25% |
| 1993 Q3 | 5.6 Million USD | 3.7% |
| 1993 FY | 5.1 Million USD | 41.67% |
| 1993 Q2 | 5.4 Million USD | 5.88% |
| 1993 Q4 | 4.4 Million USD | -21.43% |
| 1992 Q1 | 3.6 Million USD | 9.09% |
| 1992 Q3 | 4.3 Million USD | 7.5% |
| 1992 Q2 | 4 Million USD | 11.11% |
| 1992 Q4 | 4.8 Million USD | 11.63% |
| 1992 FY | 3.6 Million USD | 71.43% |
| 1991 Q4 | 3.3 Million USD | 26.92% |
| 1991 Q3 | 2.6 Million USD | 13.04% |
| 1991 FY | 2.1 Million USD | 90.91% |
| 1991 Q2 | 2.3 Million USD | 9.52% |
| 1991 Q1 | 2.1 Million USD | 23.53% |
| 1990 Q2 | 1.3 Million USD | 18.18% |
| 1990 Q3 | 1.4 Million USD | 7.69% |
| 1990 Q4 | 1.7 Million USD | 21.43% |
| 1990 FY | 1.1 Million USD | 120.0% |
| 1990 Q1 | 1.1 Million USD | 22.22% |
| 1989 Q1 | 500 Thousand USD | 0.0% |
| 1989 Q4 | 900 Thousand USD | 12.5% |
| 1989 Q3 | 800 Thousand USD | 14.29% |
| 1989 Q2 | 700 Thousand USD | 40.0% |
| 1989 FY | 500 Thousand USD | -92.06% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Cosmos Health Inc. | 3.03 Million USD | -533220.638% |
| Safety Shot Inc | 304.9 Thousand USD | -5309092.639% |
| Bright Green Corporation | 201.78 Thousand USD | -8022429.153% |
| Embecta Corp. | 1.62 Billion USD | -895.946% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | -5127.549% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | -17674.276% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | -3203.95% |
| Dynavax Technologies Corporation | 252.41 Million USD | -6313.211% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | -3127.64% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | -121377.563% |
| Pacira BioSciences, Inc. | 513.79 Million USD | -3050.686% |
| PainReform Ltd. | 30 Thousand USD | -53960233.333% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -3003063.06% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -3003063.06% |
| SCYNEXIS, Inc. | 12.15 Million USD | -133036.771% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -13820644.649% |
| Journey Medical Corporation | 14.62 Million USD | -110610.573% |
| Alpha Teknova, Inc. | 13.25 Million USD | -122065.12% |
| Procaps Group, S.A. | 28.41 Million USD | -56880.289% |
| Theratechnologies Inc. | 51.26 Million USD | -31479.758% |
| Harrow Health, Inc. | 183.17 Million USD | -8737.65% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -18606911.494% |
| Biofrontera Inc. | 804 Thousand USD | -2013345.274% |
| DURECT Corporation | 2.7 Million USD | -599015.47% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -48665.213% |
| Cronos Group Inc. | 1.55 Million USD | -1038264.336% |
| OptiNose, Inc. | 611 Thousand USD | -2649343.535% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | -3148.607% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -47247.47% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -3557724.176% |
| Organogenesis Holdings Inc. | 60.74 Million USD | -26549.272% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | -126526.39% |
| Radius Health, Inc. | 339.66 Million USD | -4665.902% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | -157709.515% |
| Phibro Animal Health Corporation | 458.28 Million USD | -3432.291% |
| Procaps Group S.A. | 28.41 Million USD | -56880.289% |
| Alvotech | 1.02 Billion USD | -1475.076% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -247727.618% |
| Rockwell Medical, Inc. | 8.29 Million USD | -195102.001% |
| Aytu BioPharma, Inc. | 10.87 Million USD | -148728.721% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -4817915.959% |
| Tilray Brands, Inc. | 287.93 Million USD | -5522.137% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | -13332.993% |
| Shineco, Inc. | 10.01 Million USD | -161500.913% |
| PetIQ, Inc. | 437.82 Million USD | -3597.433% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | -7708519.048% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -6167.17% |
| Alimera Sciences, Inc. | 64.48 Million USD | -25002.11% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | -41931.729% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -11983185.094% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -235968.845% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -2248247.222% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -71998209.909% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | -49314.226% |
| Hempacco Co., Inc. | 5.93 Million USD | -272840.436% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | -1475.076% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | -28696.25% |
| Lantheus Holdings, Inc. | 616.12 Million USD | -2527.414% |
| Currenc Group, Inc. | 2.5 Million USD | -645622.692% |
| Kamada Ltd. | 7.43 Million USD | -217540.495% |
| Indivior PLC | 235.66 Million USD | -6769.063% |
| Evoke Pharma, Inc. | 5 Million USD | -323662.0% |
| Flora Growth Corp. | 942 Thousand USD | -1718381.953% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -71998209.909% |
| Evolus, Inc. | 120.35 Million USD | -13349.846% |
| HUTCHMED (China) Limited | 48.18 Million USD | -33492.936% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | -2647.476% |
| Akanda Corp. | 2.49 Million USD | -648161.722% |